75 related articles for article (PubMed ID: 1361441)
1. Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat.
Ahlenius S; Wijkström A
Eur J Pharmacol; 1992 Nov; 222(1):69-74. PubMed ID: 1361441
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat.
Ahlenius S; Salmi P
Eur J Pharmacol; 1994 Aug; 260(2-3):177-81. PubMed ID: 7988642
[TBL] [Abstract][Full Text] [Related]
3. In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptors.
Ahlenius S; Henriksson I; Magnusson O; Salmi P
Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):15-9. PubMed ID: 10082223
[TBL] [Abstract][Full Text] [Related]
4. Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine.
Wadenberg ML; Ahlenius S; Svensson TH
Psychopharmacology (Berl); 1993; 110(3):273-9. PubMed ID: 7831419
[TBL] [Abstract][Full Text] [Related]
5. Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission.
Ericson E; Ahlenius S
Brain Res; 1999 Mar; 822(1-2):200-9. PubMed ID: 10082897
[TBL] [Abstract][Full Text] [Related]
6. Quinpirole--a 5-HT receptor antagonist?
Ahlenius S; Hillegaart V; Wijkström A
Neurosci Lett; 1991 May; 126(1):57-9. PubMed ID: 1678151
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of brain dopamine autoreceptors by remoxipride administration in reserpine-treated male rats.
Ahlenius S; Ericson E; Wijkström A
J Pharm Pharmacol; 1993 Mar; 45(3):237-9. PubMed ID: 8097786
[TBL] [Abstract][Full Text] [Related]
8. Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat.
Ahlenius S; Hillegaart V; Wijkström A
Naunyn Schmiedebergs Arch Pharmacol; 1989 May; 339(5):551-6. PubMed ID: 2570361
[TBL] [Abstract][Full Text] [Related]
9. Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects.
Svensson K; Eriksson E; Carlsson A
Neuropharmacology; 1993 Oct; 32(10):1037-45. PubMed ID: 7905192
[TBL] [Abstract][Full Text] [Related]
10. Pre- and postsynaptic actions of a partial D2 receptor agonist in reserpinized young rats: longevity of agonistic effects.
Farley CM; Baella SA; Wacan JJ; Crawford CA; McDougall SA
Brain Res; 2006 Dec; 1124(1):37-44. PubMed ID: 17070785
[TBL] [Abstract][Full Text] [Related]
11. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
12. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
[TBL] [Abstract][Full Text] [Related]
13. The effects of umespirone as a potential anxiolytic and antipsychotic agent.
Barnes NM; Costall B; Domeney AM; Gerrard PA; Kelly ME; Krähling H; Naylor RJ; Tomkins DM; Williams TJ
Pharmacol Biochem Behav; 1991 Sep; 40(1):89-96. PubMed ID: 1685786
[TBL] [Abstract][Full Text] [Related]
14. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
Mignon L; Wolf WA
Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404
[TBL] [Abstract][Full Text] [Related]
15. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
Lee J; Di Marzo V; Brotchie JM
Neuropharmacology; 2006 Sep; 51(3):557-65. PubMed ID: 16806299
[TBL] [Abstract][Full Text] [Related]
16. Neurochemical and behavioural evidence for an agonist action of 1-[2-(4-aminophenyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine (LY 165163) at central 5-HT receptors.
Hutson PH; Donohoe TP; Curzon G
Eur J Pharmacol; 1987 Jun; 138(2):215-23. PubMed ID: 3113985
[TBL] [Abstract][Full Text] [Related]
17. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.
Natesan S; Svensson KA; Reckless GE; Nobrega JN; Barlow KB; Johansson AM; Kapur S
J Pharmacol Exp Ther; 2006 Aug; 318(2):810-8. PubMed ID: 16648369
[TBL] [Abstract][Full Text] [Related]
18. Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists.
Hubbard CA; Trugman JM
Mov Disord; 1993 Oct; 8(4):473-8. PubMed ID: 7901761
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and functional studies on EMD 49,980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems.
Seyfried CA; Greiner HE; Haase AF
Eur J Pharmacol; 1989 Jan; 160(1):31-41. PubMed ID: 2565817
[TBL] [Abstract][Full Text] [Related]
20. Repeated quinpirole treatment: locomotor activity, dopamine synthesis, and effects of selective dopamine antagonists.
Rowlett JK; Mattingly BA; Bardo MT
Synapse; 1995 Jul; 20(3):209-16. PubMed ID: 7570352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
